Acute bacterial infection of the prostate — fever, pelvic pain, exquisitely tender prostate; treat with prolonged antibiotics.
Also known as: acute prostatitis, bacterial prostatitis, ABP
Overview
Acute bacterial infection of the prostate gland (NIH Category I), typically presenting with systemic illness and lower urinary tract symptoms. Distinct from chronic bacterial prostatitis (II), chronic pelvic pain syndrome (III), and asymptomatic inflammatory prostatitis (IV).
Epidemiology
Most common in men 20-40 and >70 years. Accounts for ~5% of all prostatitis cases. Often complicates urinary instrumentation or BPH.
🔒 Free preview limit reached
Keep reading — start your free trial
You've read your 2 free diagnosis previews. Create your free account to unlock the full Acute Bacterial Prostatitis outline — plus all 514 diagnoses, 3,500+ board-style questions, flashcards, and an AI tutor. Your 7-day free trial includes everything, and there's no credit card required.
Recent urinary catheterization or instrumentation (cystoscopy, TRUS biopsy)
Indwelling catheter
Anal intercourse (especially with insertive partner)
Phimosis, urethral strictures
Immunocompromise (diabetes, HIV)
Prior urinary tract infection
Pathophysiology
Ascending infection from urethra (most common), reflux of infected urine through prostatic ducts, or hematogenous seeding. Common organisms: E. coli (most common, ~60-80%), Klebsiella, Proteus, Pseudomonas, Enterococcus; Neisseria gonorrhoeae and Chlamydia in younger sexually active men.
Clinical presentation
Symptoms
Fever, chills, rigors
Lower abdominal, perineal, or low back pain
Dysuria, frequency, urgency, hematuria
Hesitancy, weak stream, retention
Painful defecation, painful ejaculation
Generalized malaise, myalgias
Signs / physical exam
Fever, tachycardia, possibly hypotension if septic
Exquisitely tender, warm, boggy, edematous prostate on gentle DRE
Suprapubic tenderness, distended bladder if retention
AVOID prostatic massage — risk of bacteremia
Classic findings
Older man (or younger with recent instrumentation) with fever, perineal pain, urinary symptoms, and exquisitely tender prostate on DRE.
Differential diagnosis
Acute pyelonephritis — CVA tenderness, fever; same organisms; can coexist with prostatitis
Urinary tract infection (cystitis) — Dysuria without prostate tenderness or fever
Urinalysis with leukocyte esterase, nitrites; urine culture and sensitivity
CBC (leukocytosis), BMP, lactate
Blood cultures if febrile/septic
PSA often markedly elevated during infection — defer screening until resolution
NAAT for GC/CT in sexually active younger men
HIV, syphilis screening in at-risk populations
Imaging
Often not needed initially if responsive to therapy
Transrectal ultrasound or pelvic CT/MRI — if abscess suspected (persistent fever/symptoms after 48-72 h of antibiotics, palpable fluctuance, immunocompromise)
Post-void residual / renal ultrasound if retention or AKI
Diagnostic algorithm
NIH Category
Diagnosis
Key Features
Treatment
I — Acute bacterial prostatitis
Acute febrile illness with UTI
Fever, tender prostate; positive urine culture
Antibiotics × 4-6 weeks (fluoroquinolone or TMP-SMX)
II — Chronic bacterial prostatitis
Recurrent UTIs with same organism, episodic
Pelvic discomfort between flares; positive cultures intermittently
Prolonged antibiotics × 4-12 weeks
IIIa — Inflammatory CPPS
Chronic pelvic pain >3 mo, WBCs in EPS/VB3, negative cultures
No identifiable infection
Alpha-blocker, NSAID, multimodal
IIIb — Non-inflammatory CPPS
Chronic pelvic pain, no WBCs, negative cultures
May involve pelvic floor dysfunction
Multimodal therapy
IV — Asymptomatic inflammatory
Incidental finding on biopsy or EPS WBCs
Asymptomatic
Usually no treatment
NIH classification of prostatitis syndromes.
Treatment
First-line
Outpatient (mild-moderate, hemodynamically stable, no abscess, tolerating PO):
• Fluoroquinolone — ciprofloxacin 500 mg PO BID OR levofloxacin 500 mg PO daily × 4-6 weeks
• OR trimethoprim-sulfamethoxazole DS BID × 4-6 weeks
• Broad-spectrum IV — piperacillin-tazobactam, ceftriaxone, OR cefepime ± aminoglycoside (gentamicin)
• Transition to oral fluoroquinolone or TMP-SMX once clinically improving
• Total duration 4-6 weeks (some sources 2-4 weeks for acute, longer for chronic)
Younger sexually active men: ceftriaxone 500 mg IM + doxycycline 100 mg PO BID × 10-14 days for GC/CT coverage
Prostatic abscess
Suspect if symptoms persist despite 48-72 h of appropriate antibiotics
Diagnosis: TRUS or CT/MRI pelvis
Drainage: transrectal or transperineal aspiration/drainage; transurethral resection in some cases
Continue IV antibiotics with anaerobic coverage
Common in diabetics, immunocompromised, HIV patients
Second-line / adjunct
Adjust antibiotics based on culture sensitivities
Antipyretics, analgesics, hydration
Stool softeners to reduce defecation pain
Urinary retention: SUPRAPUBIC catheter preferred (urethral catheter may worsen infection); if not feasible, gentle small-caliber Foley
Alpha-blocker (tamsulosin) for voiding symptoms
Complications
Sepsis, septic shock
Prostatic abscess
Acute urinary retention
Chronic bacterial prostatitis (~5% develop)
Epididymo-orchitis
Bacteremia and metastatic infection
Pyelonephritis
PANCE pearls
AVOID vigorous prostatic massage in acute bacterial prostatitis — can precipitate bacteremia and sepsis.
Fluoroquinolones and TMP-SMX penetrate prostatic tissue well; many other antibiotics (cephalosporins, penicillins) penetrate poorly into normal prostate but enter inflamed prostatic tissue more readily during acute infection.
PSA often markedly elevated during acute prostatitis — defer prostate cancer screening for 6-8 weeks after resolution.
For urinary retention complicating acute bacterial prostatitis, suprapubic catheter is preferred over urethral catheter (urethral catheter may worsen inflammation and bacteremia).
Treatment duration is 4-6 weeks for acute bacterial prostatitis — longer than typical UTI because of biofilm and tissue penetration challenges.
Failure to improve in 48-72 hours warrants imaging to rule out prostatic abscess.
Younger sexually active men require coverage for Neisseria gonorrhoeae and Chlamydia trachomatis (ceftriaxone + doxycycline).
References
AUA 2010 — Diagnosis and Treatment of Prostatitis: AUA Guideline; subsequent updates
EAU 2024 — EAU Guidelines on Urological Infections (Bonkat et al., 2024)
Educational use only. This outline is a study aid for PA students and is not medical advice or a substitute for clinical judgment. FirstPassPA is an independent study tool and is not affiliated with, endorsed by, or sponsored by NCCPA. PANCE® and PANRE® are registered trademarks of the National Commission on Certification of Physician Assistants.